Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab plus methotrexate versus methotrexate alone in methotrexate-naive active rheumatoid arthritis
2006-005353-30Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Ocrelizumab + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: Change from baseline in modified total Sharp score at Week 52. Started Apr 2007; status: completed.
02
Drugs
ocrelizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-005353-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005353-30.